In Vitro: Aspirin+Celecoxib inhibited cell proliferation, induced apoptosis, arrested the cell cycle at the G0/G1 phase, and suppressed cell migration by targeting GRP78, enhancing ROS generation, and inhibiting the ERK-MAPK pathway. In Vivo: The combination therapy suppressed tumor growth, showing superior efficacy compared to monotherapy with either aspirin or celecoxib. The gene discussed is HSPA5; the disease is neoplasm.